The Industry Is Set to Surpass $1.68 Trillion by 2030
Innovation from start-ups and established businesses is driving the biotechnology industry’s significant growth. Valued at $859.94 billion in 2022, the global biotech industry is projected to reach $1,683.52 billion by 2030, thanks to strong government support, improved approval processes, standardisation of clinical trials, and rising demand for personalised medicine and orphan drugs.
Alnylam: Revolutionising Genetic Disease Therapies
Alnylam is a leading biotechnology company developing RNA interference therapies for a variety of genetic diseases. Founded in 2002, the company has FDA-approved drugs, including Onpattro for hereditary transthyretin-mediated amyloidosis. Collaborations with Sanofi and Regeneron have expanded the use of RNAi therapies.
Vutrisiran, an RNAi therapy for ATTR amyloidosis, was approved in 2022. Late-stage candidates such as Fitusiran for haemophilia and Cemdisiran for IgA anaemia show promise, with FDA approval expected in 2023. Given its unique RNAi therapies, Biospace believes Alnylam could be a top takeover candidate in 2023, with Novartis and Pfizer as potential suitors.
Biogen: Advancing Neurological Disease Therapies
Biogen, a leading biotechnology company founded in 1978, is known for developing therapies for neurological and neurodegenerative diseases, including the first multiple sclerosis treatment, Avonex. Through partnerships, expected product launches in 2023 include the Alzheimer’s drug Lecanemab with Eli Lilly and the antidepressant Zaranolone with SageTx. Biogen is also seeking accelerated approval for Tofersen, a potential first-in-class therapy for the genetic cause of ALS, SOD1.
Wealth Aggregation: Simple, Dynamic, and Secure Beyond Compare. Discover the Altoo Wealth Platform!
BioNTech: Pioneering mRNA Immunotherapy
BioNTech, founded in 2008, is known for developing personalised immunotherapy for cancer and infectious diseases. The company rose to prominence in 2020 when it co-developed the COVID-19 vaccine, Comirnaty, with Pfizer. Leveraging the success of its mRNA technology, BioNTech has partnered with Roche and Sanofi to develop mRNA-based therapeutics. Its pipeline includes a seasonal flu vaccine in Phase 3, BNT161, and a cancer vaccine targeted for launch in 2030. The company’s partnership with the UK government is accelerating trials of personalised mRNA therapies for cancer and infectious disease vaccines.
Insilico: Revolutionising AI-Powered Drug Discovery
Founded in 2014, Insilico Medicine uses artificial intelligence and machine learning to accelerate drug discovery and development, combining computational and experimental methods to design and optimise drugs. Collaborations with giants such as GlaxoSmithKline and the University of Toronto apply their AI approach to drug discovery. Focused on cancer, fibrosis, and ageing-related diseases, Insilico is recognised for efficient, cost-effective drug development.
Moderna: Leading the mRNA Therapeutics Revolution
Founded in 2010, Moderna specialises in the development of mRNA therapeutics and vaccines and has made significant contributions to mRNA technology, personalised cancer vaccines, and novel infectious disease therapies. The company has achieved global recognition for its COVID-19 vaccine, which was developed in collaboration with the U.S. National Institutes of Health. With 48 programmes, including mRNA vaccines for infectious diseases and oncology, Moderna continues to pioneer mRNA science.
